Skip to content

The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects

The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02102880
Enrollment
220
Registered
2014-04-03
Start date
2015-03-31
Completion date
2023-09-02
Last updated
2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Keywords

Genetic Association Studies

Brief summary

Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Given that it is known that impaired regulation of choroidal vascular tone is present in patients with AMD, the current study seeks to investigate whether genetic polymorphisms in risk alleles for AMD are associated with altered choroidal blood flow regulation in healthy subjects. For this purpose a total of 220 healthy volunteers will be included. Choroidal blood flow regulation will be evaluated by measuring choroidal blood flow during isometric exercise. In addition, flicker induced vasodilatation will be studied and retinal vessel calibers will assessed, as well as retinal thickness and macular pigment optical density.

Interventions

GENETICthe polymerase chain reaction (PCR)

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women aged between 18 and 45 years, nonsmokers * Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Systolic blood pressure \< 160 mmHg, diastolic blood pressure \< 90 mmHg * Normal ophthalmic findings, ametropia less than 3 diopters

Exclusion criteria

* Regular use of medication * Abuse of alcoholic beverages * Participation in a clinical trial in the 3 weeks preceding the study * Treatment in the previous 3 weeks with any drug (except hormonal contraceptives) * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks * History or family history of epilepsy * Pregnancy, planned pregnancy or lactating

Design outcomes

Primary

MeasureTime frame
Choroidal blood flow during isometric exercise (LDF)1 day

Secondary

MeasureTime frame
Flicker induced vasodilatation, expressed as percent change to baseline (DVA)1 day
Genotyping (PCR)1 day
Retinal vessel calibers and AV- ratio (DVA)1 day
Laser Speckle Flowmetry (LSFG)1 day

Countries

Austria

Contacts

Primary ContactGerhard Garhofer, MD
gerhard.garhoefer@meduniwien.ac.at0034140400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026